Off-Label Promotion Remains Vulnerable To Prosecution, DoJ Says

The information dissemination provisions in the FDA Modernization Act do not provide "carte blanche" for manufacturers to promote drugs off-label, the Department of Justice said in a recent letter to the Washington Legal Foundation